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Retinitis pigmentosa (RP) is a group of hereditary 
diseases with an incidence of approximately 1:4,000 [1-4]. 
Although the clinical variation is high, RP is generally char-
acterized by complaints of night blindness and peripheral 
visual field loss caused by progressive rod photoreceptor 
degeneration. In later stages of the disease, cones may also 
degenerate, which results in a decrease of central and color 
vision. The disease can be transmitted in all Mendelian 
patterns, including autosomal recessive in 50–60% of RP 
patients, autosomal dominant in 30–40%, and X-linked in 
5–15% [1]. In addition, mitochondrial inheritance has been 
described in <1% of RP patients [5], and a few digenic cases 
have been reported [6,7]. To date, over 2,300 mutations in 
45 genes have been associated with autosomal recessive RP 
(arRP; RetNet) [8]. This allelic and genetic heterogeneity 
complicates mutation detection in RP patients, since the 
phenotype is often not specific enough to link the disease 
to a particular gene. Furthermore, only just over 50% of the 
arRP cases can be linked to mutations in these genes [9,10].
Over time, multiple genotyping techniques have been 
developed to identify causative mutations in genes associated 
with RP, such as single-strand conformation analysis [11], 
denaturing high-performance liquid chromatography (HPLC) 
[12], resequencing microarrays [13], and arrayed primer 
extension (APEX) analysis [14-16]. Recently, next-generation 
sequencing (NGS) has exhibited potential in identifying caus-
ative mutations in a selected gene set (targeted NGS) [17] and 
in the whole exome [18].
Diagnostic genetic testing in nonsyndromic RP patients 
using the APEX microarray technology is popular, since it 
is a relatively low cost technique that enables screening of 
numerous mutations in multiple genes simultaneously. In the 
last decade, APEX chips have been developed for mutation 
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Purpose: To determine the efficacy of multiple versions of a commercially available arrayed primer extension (APEX) 
microarray chip for autosomal recessive retinitis pigmentosa (arRP).
Methods: We included 250 probands suspected of arRP who were genetically analyzed with the APEX microarray 
between January 2008 and November 2013. The mode of inheritance had to be autosomal recessive according to the 
pedigree (including isolated cases). If the microarray identified a heterozygous mutation, we performed Sanger sequenc-
ing of exons and exon–intron boundaries of that specific gene. The efficacy of this microarray chip with the additional 
Sanger sequencing approach was determined by the percentage of patients that received a molecular diagnosis. We also 
collected data from genetic tests other than the APEX analysis for arRP to provide a detailed description of the molecular 
diagnoses in our study cohort.
Results: The APEX microarray chip for arRP identified the molecular diagnosis in 21 (8.5%) of the patients in our co-
hort. Additional Sanger sequencing yielded a second mutation in 17 patients (6.8%), thereby establishing the molecular 
diagnosis. In total, 38 patients (15.2%) received a molecular diagnosis after analysis using the microarray and additional 
Sanger sequencing approach. Further genetic analyses after a negative result of the arRP microarray (n = 107) resulted in 
a molecular diagnosis of arRP (n = 23), autosomal dominant RP (n = 5), X-linked RP (n = 2), and choroideremia (n = 1).
Conclusions: The efficacy of the commercially available APEX microarray chips for arRP appears to be low, most likely 
caused by the limitations of this technique and the genetic and allelic heterogeneity of RP. Diagnostic yields up to 40% 
have been reported for next-generation sequencing (NGS) techniques that, as expected, thereby outperform targeted 
APEX analysis.
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analysis of the ABCA4 gene (GeneID: 24; OMIM 601691) in 
autosomal recessive Stargardt disease or cone–rod dystrophy 
[16,19], as well as for multiple gene microarrays for Leber 
congenital amaurosis (LCA) [15,20], Bardet–Biedl syndrome 
(BBS) [21], Usher syndrome [22], and autosomal dominant 
and recessive RP [23]. The efficacy with which these APEX 
chips lead to a molecular diagnosis is variable for the different 
disorders.
Identification of the genetic cause in these patients has 
become more important over time. This not only allows for a 
more accurate prognosis and appropriate genetic counseling 
for patients and their families, but also provides crucial 
information with regard to upcoming genetic therapies. The 
aim of this study was to evaluate the efficiency of the micro-
array chip for arRP in a cohort of recessive and isolated RP 
probands.
METHODS
Patients: For this study, we selected unrelated patients from 
the departments of ophthalmology of the Radboud Univer-
sity Medical Center (Nijmegen, Netherlands), Erasmus 
Medical Center (Rotterdam, Netherlands), and Rotterdam 
Eye Hospital (Rotterdam, Netherlands) that were clinically 
suspected of RP and were analyzed with an arRP microarray 
between January 2008 and November 2013. The microarray 
screenings were requested by the ophthalmologist who 
examined the patient when RP was suspected based on the 
simultaneous occurrence of at least two of the following 
criteria: (1) a history of night blindness or peripheral visual 
field loss, (2) a positive family history for RP, (3) perimetric 
results compatible with RP, and (4) reduced responses on 
electroretinography (ERG). We included both the probands 
of families that were suspected of RP with an autosomal 
recessive inheritance pattern and isolated cases; meanwhile, 
families with presumed dominant or X-linked inheritance 
patterns were excluded. Only probands were included; other 
patients within the same family were excluded, as well as 
patients with insufficient clinical data. For this retrospective 
study, the local ethics committee ruled that approval was not 
required, and according to the tenets of the Declaration of 
Helsinki, all participants gave informed consent for the use 
of their data.
For the selection procedure described above, we 
collected data from the medical records, including history 
and age of onset, best-corrected visual acuity (BCVA), fundus 
appearance, and full-field ERG results. Full-field ERG was 
performed according the International Society for Clinical 
Electrophysiology of Vision (ISCEV) standards [24].
Genetic microarray chip analyses: DNA was extracted from 
leukocytes acquired from peripheral venous blood samples 
according to automated nucleic acid isolation based on 
magnetic bead technology (Chemagic MSM I, Perkin Elmer 
chemagen Technologie GmbH, Baesweiler, Germany). We 
performed mutational screening using a commercially avail-
able genotyping microarray chip based on APEX technology 
(Asper Biotech, Tartu, Estonia) according to a protocol 
including polymerase chain reaction (PCR) DNA amplifica-
tion, fragmentation of the amplification products and hybrid-
ization with the microarray slide as described previously [15]. 
An APEX reaction is based on a single base extension prin-
ciple, which provides highly specific discrimination without 
allele-specific hybridization. In a single multiplex reaction, 
hundreds to thousands of variants can be analyzed simulta-
neously. The microarray chips used in this study included 
known pathogenic mutations in the coding regions and adja-
cent intronic sequences of genes associated with arRP.
The microarray chip initially included 501 mutations 
in 16 genes in 2006 [25], but was regularly updated as new 
mutations were discovered. The latest version (version 6.0) 
included 710 mutations in 28 genes (Table 1). During the 
inclusion period of this study, five versions of this array have 
been used, as follows: versions 4.0 (between January and 
April 2008), 4.1 (between April 2008 and February 2009), 5.0 
(between February 2009 and September 2010), 5.3 (between 
September 2010 and July 2012), and 6.0 (between July 2012 
and November 2013). Sanger sequencing was performed to 
confirm each mutation that was identified by the microarray 
chip. If only a single heterozygous mutation in a certain 
gene was found, all exons and intron–exon boundaries of 
this gene were analyzed with Sanger sequencing to search 
for the mutation on the second allele. The pathogenicity of a 
mutation was determined by our in-house protocol based on 
the criteria described by Cotton et al. [26], which evaluates 
pathogenicity according to evolutionary conservation of the 
altered nucleotide (phylogenetic profiling [PhyloP] score), 
the nature of the change at the amino acid level (Grantham 
score), and information from online in silico prediction tools 
SIFT and Polyphen-2. The effects of mutations on splice sites, 
if applicable, were determined by five predictor programs 
(SpliceSiteFinder-like, MaxEntScan, NNSPLICE, Gene-
Splicer, and Human Splicing Finder) as provided in Alamut 
Visual (various versions, Interactive Biosoftware, Rouen, 
France). Reference sequences as provided by Alamut Visual 
(Interactive Biosoftware) have been used. Genes and muta-
tions were annotated according to the HUGO Gene Nomen-
clature Committee (HGNC) and Human Genome Variation 
Society (HGVS) nomenclatures, respectively. The efficiency 
of each version of the microarray chip was determined by the 
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number of patients that had a molecular diagnosis after the 
analysis with the microarray chip. Patients were considered 
to have a molecular diagnosis when it was plausible that both 
alleles had been identified by a variant that was predicted 
to be pathogenic, meaning that the variants were predicted 
to significantly reduce or nullify the function of the protein. 
Identification of two pathogenic mutations (in combination 
with the presence of the RP phenotype) was considered 
pathogenic; segregation analysis—to evaluate whether the 
identified mutations are situated on separate alleles—was 
performed in some but not all families.
Further genetic analyses: To further evaluate the molecular 
diagnoses found in our study cohort, we also collected data 
from the genetic tests that had been performed after a nega-
tive result of the arRP microarray chip in these patients. The 
tests included targeted NGS (n = 16), microarray analyses for 
autosomal dominant RP, LCA, BBS, Usher syndrome, and 
ABCA4 mutation analysis (n = 28), or Sanger sequencing of 
selected genes (n = 88). The microanalyses were performed 
using the microarray chips available from Asper (Asper 
Biotech). Targeted NGS was performed by sequencing the 
exome with a 5500×l Genetic Analyzer (Life Technologies, 
Table 1. Overview Of The genes analyzed by The laTesT aPeX micrOarray chiP 
fOr auTOsOmal recessive reTiniTis PigmenTOsa (versiOn 6.0).
Gene symbol Full gene name Number of mutations included 
in chip
ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 1
AIPL1 Aryl hydrocarbon receptor interacting protein-like 1 1
CERKL Ceramide kinase-like 5
CNGA1 Cyclic nucleotide gated channel alpha 1 5
CNGA3 Cyclic nucleotide gated channel alpha 3 1
CNGB1 Cyclic nucleotide gated channel beta 1 3
CNGB3 Cyclic nucleotide gated channel beta 3 1
CRB1 Crumbs homolog 1 114
EYS Eyes shut homolog 68
GRK1 G protein-coupled receptor kinase 1 1
IMPG2 Interphotoreceptor matrix proteoglycan 2 6
LRAT Lecithin retinol acyltransferase (phosphatidyl-choline-retinol O-acyltransferase) 3
MERTK C-mer proto-oncogene tyrosine kinase 14
PDE6A Phosphodiesterase 6A, cGMP-specific, rod, alpha 22
PDE6B Phosphodiesterase 6B, cGMP-specific, rod, beta 28
NR2E3 Nuclear receptor subfamily 2, group E, member 3 31
PROM1 Prominin 1 2
RBP3 Retinol binding protein 3, interstitial 1
RDH12 Retinol dehydrogenase 12 (all-trans/9-cis/11-cis) 45
RGR Retinal G protein coupled receptor 7
RHO Rhodopsin 2
RLBP1 Retinaldehyde binding protein 1 13
RP1 Retinitis pigmentosa 1 3
RPE65 Retinal pigment epithelium-specific protein 65 kDa 100
SAG S-antigen; retina and pineal gland (arrestin) 4
TULP1 Tubby like protein 1 25
CLRN1 Clarin 1 12
USH2A Usher syndrome 2A 192
Total: 28  Total: 710
ATP, Adenosine triphosphate; cGMP, cyclic guanosine monophosphate; kDA, kiloDalton.
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Carlsbad, CA) after DNA enrichment with the Agilent Sure-
SelectXT Human All Exon 50Mb Kit (Agilent Technologies, 
Santa Clara, CA). Data were analyzed using LifeScope soft-
ware (Life Technologies). Following this, the variants of 160 
genes known to be involved in retinal disease were selected 
and ordered according to predicted pathogenicity. All identi-
fied mutations were confirmed by Sanger sequencing.
RESULTS
We included 250 probands (136 males, 54%) with the clinical 
diagnosis of autosomal recessive or isolated RP. Seven 
patients were analyzed with microarray version 4.0, 12 with 
version 4.1, 86 with version 5.0, 98 with version 5.3, and 47 
with version 6.0. All mutations identified by the microarray 
chip were subsequently confirmed with Sanger sequencing.
Combining the results of all versions of the microarray 
chip, we identified mutations in 68 patients (27.7%). A total 
of 21 arRP patients (8.5%) received a confirmed molecular 
diagnosis by means of identification of a homozygous or two 
heterozygous pathogenic mutations. In 47 patients (18.8%), 
a single heterozygous pathogenic mutation was detected. 
In most patients (182, 72.8%), however, the microarray 
analysis did not reveal any causative mutation (Table 2). 
Additional Sanger sequencing when a heterozygous mutation 
was identified by the microarray chip resulted in a second 
pathogenic mutation in 17 patients (6.8%, Table 2). The 
microarray missed two (11.8%) of these mutations, resulting 
in a maximum sensitivity of 95.7%. However, to determine 
the exact sensitivity, all genes tested on the microarray chip 
should be sequenced. In total, microarray screening with 
the additional Sanger sequencing approach identified the 
molecular diagnosis in 38 (15.2%) of the arRP patients. Table 
2 summarizes the numbers of patients with two, one, or no 
mutations after microarray screening for each microarray 
version, as well as the numbers of solved cases after addi-
tional Sanger sequencing.
In this study, we identified 65 different mutations in 12 
genes (Table 3). Most mutations were identified in USH2A 
(48.5%; Gene ID: 7399 ; OMIM 608400), PDE6A (17.6%; 
Gene ID: 5145; OMIM 180071), and CRB1 (10.3%; Gene 
ID: 23418; OMIM 604210). Of the 65 variants identified in 
this study, 39 (60%) were missense mutations, 10 (15.4%) 
had effects on splicing, 9 (13.8%) caused a premature stop 
(nonsense mutations), and 7 (10.8%) resulted in a shift of the 
open reading frame. Fifty-nine mutations are (likely to be) 
pathogenic, whereas 6 mutations appear to have no significant 
effects on protein function (Table 3). These mutations may 
have been included based on unpublished in-house databases 
of the collaborators. The other eight mutations were identified 
by Sanger sequencing.
Further genetic analyses: Additional genetic tests were 
performed in 107 patients (43.6%) subsequent to the micro-
array analysis for arRP. An overview is provided in Table 4. 
The tests were selected based on the lack of family history or 
the acquisition of new history and ocular examination details 
after running the arRP APEX. These genetic tests resulted in 
a molecular diagnosis in 31 patients (30%), including arRP in 
23 patients (21.5%), autosomal dominant RP in five patients 
(4.7%), X-linked RP in two patients (1.9%), and choroider-
emia in one patient (0.9%). The targeted NGS approach that 
covered 160 genes associated with hereditary blindness 
resulted in a molecular diagnosis in 12 patients (75%, Table 
4).
Table 2. efficacy in The idenTificaTiOn Of The geneTic cause Of auTOsOmal recessive reTiniTis PigmenTOsa 
by The asPer micrO-array chiP wiTh and wiThOuT addiTiOnal sanger sequencing fOr This disease.
Chip 
version
Number of 
patients
Number of cases after microarray analysis (%) Number of genetically solved cases 
by additional Sanger sequencing 
(%)†
Genetically solved* Heterozygous No mutations
4 7 0 (0) 0 (0) 7 (100) 0 (0)
4.1 12 3 (25) 2 (16.7) 7 (58.3) 0 (0)
5 86 4 (4.7) 20 (23.3) 62 (72.1) 4 (4.7)
5.3 98 11 (11.2) 16 (16.3) 71 (72.4) 11 (11.2)
6 47 3 (6.4) 9 (19.1) 35 (74.4) 2 (4.3)
      
Overall 250 21 (8.5) 47 (18.8) 182 (72.8) 17 (6.8)
*Patients were considered genetically ‘solved’ if homozygous or compound heterozygous mutations were identified. Segregation analysis 
was performed in some but not all families. † Number of patients in whom the mutation on the second allele was identified by Sanger 
sequencing after identification of a heterozygous mutation by microarray screening.
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DISCUSSION
Only a decade ago, microarray screening boosted diag-
nostic genetic analysis in genetic heterogeneous disorders 
such as RP by facilitating reliable fast analysis of multiple 
genes simultaneously with much lower costs than Sanger 
sequencing of the same genes. Nowadays, high-throughput 
NGS techniques like exome sequencing have become avail-
able and are selectively used in a diagnostic setting. The 
microarray technique, however, still has a prominent posi-
tion in the diagnostic genetic analysis of RP, since NGS is 
currently only available for a small number of patients and 
has long lead times (>6 months). Therefore, we evaluated the 
efficiency of microarray screening in arRP and isolated RP 
cases to determine its place in the array of diagnostic genetic 
tests currently available.
The low efficacy of 15.2% solved cases after microarray 
screening and additional Sanger sequencing found in this 
study can be attributed to the method’s limitations in covering 
the genetic and clinical characteristics of autosomal reces-
sive and simplex RP. First, the chip only analyzes a fixed 
set of mutations. The latest version of the chip includes 710 
mutations in 28 genes, whereas over 2,300 mutations in 45 
genes are associated with arRP nowadays [8] (and RetNet). 
Therefore, more frequent updates and inclusion of less 
frequent genes and mutations are necessary to increase the 
chip’s efficacy, although this will be costly and laborious to 
implement. Second, the APEX microarray approach does not 
identify variants other than the set of mutations present on 
the array. This rigid approach lowers the chance of mutation 
identification for arRP patients, since the frequency of private 
mutations is generally relatively high because of the immense 
mutational heterogeneity in arRP.
In addition to the disadvantages of the test itself, the 
heterogeneity of genetic and clinical characteristics of auto-
somal recessive and simplex RP complicates genetic analysis, 
since the correlation between a phenotype and specific muta-
tions in a specific gene may be weak. Moreover, isolated RP 
cases, which are generally considered autosomal recessive, 
may also have autosomal dominant or X-linked modes of 
inheritance. For instance, X-linked RP caused by mutations 
in RPGR (Gene ID: 7399 ; OMIM 608400) or RP2 (Gene ID: 
6102; OMIM 300757) account for 15% of male isolated cases 
with retinal degenerative disease [27], and de novo mutations 
in genes known to follow a dominant inheritance pattern 
account for 1–2% of isolated RP [17,28]. This is exemplified 
by the discovery of mutations in dominant and X-linked RP 
genes in seven isolated patients in the current study (Table 
4). An approach that enables genetic analysis of autosomal 
recessive, dominant, and X-linked cases simultaneously, such 
as NGS, would therefore be preferable.
The microarray chip analyzes defects in the genes that 
are relatively frequently mutated in arRP. Yet, this contributes 
little to the chip’s efficacy, since mutations in the majority of 
genes account only for 1–2% or less of arRP cases [1,8,29]. 
Furthermore, the older versions of the chip included muta-
tions that are considered benign (c.9262G>A in USH2A and 
c.878C>T in PDE6A, Table 3). These variants were probably 
detected in arRP cases previously, and have subsequently 
been added to the array, without a functional assessment of 
their pathogenicity, especially in the case of missense muta-
tions. Recently, it has become clear that using in silico predic-
tion tools, and especially databases with allele frequencies in 
large normal cohorts, like the Exome Variant Server (EVS), 
provides insight into the pathogenicity of a missense muta-
tion, and should be used if functional assessment is missing. 
These benign mutations lower the microarray’s efficiency, 
and should ideally be removed from the chip. The two benign 
mutations identified with the microarray in this study were 
not on later versions of the chip.
In contrast to the microarray approach, NGS techniques 
such as whole-exome sequencing can handle the heteroge-
neity of arRP and provide a thorough genetic analysis. NGS 
has been reported to identify the genetic cause in 19% to 
40% of arRP cases (and 50% to 82% of RP cases in general), 
which is significantly higher than the 15.2% solved cases 
after microarray screening and additional Sanger sequencing 
found in this study [10,17,30-36]. In whole-exome sequencing, 
all coding sequences (the exons) of all genes in the genome 
are sequenced, which enables the identification of known 
and novel mutations in known arRP genes. Mutations in 
genes that have not yet been associated with arRP can also 
be identified by this approach. In whole-genome sequencing, 
all genetic material is sequenced, including the exons as well 
as the introns, the noncoding sequences. This approach can 
theoretically solve even more arRP patients genetically, for 
instance through the identification of intronic pathologic 
mutations, which have been described in retinal degeneration 
[37-40]. Yet, the increasing number of DNA variants that will 
become available when employing these techniques poses a 
significant challenge to data interpretation.
Future perspectives of genetic testing in RP: The genetic and 
allelic heterogeneity and often nonspecific clinical appearance 
of RP complicates diagnostic genetic testing. Although APEX 
microarray analysis has been the most efficient diagnostic 
tool for RP for years, the introduction of NGS techniques 
in diagnostics have shown their superiority by identifying 
causative mutations in up to 40% of arRP cases [10,17,30-33]. 
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However, NGS comes with its own difficulties, such as data 
management and analysis of the large datasets, and confirma-
tion of the pathogenicity of identified variants [10,17,33]. The 
latter is crucial, since the large number of genes involved in 
arRP increases the risk of finding a pathogenic variant that is 
not causative, especially when considering that each person 
may be carrying ~1,500 variants in their coding sequence 
affecting protein function [41], and when considering retinal 
degeneration genes, clear-cut heterozygous pathogenic null 
mutations were reported in 1 out of 4 to 5 healthy controls that 
were analyzed with whole-genome sequencing [42]. Further-
more, the costs of data management and storage may rise with 
the use of whole-genome sequencing and the development of 
“third generation” technologies due to massive datasets [43]. 
The sequencing costs of NGS have been high initially, but 
the expenses have diminished over the years, especially since 
this technique became commercially available. Currently, 
the costs of diagnostic NGS have decreased to levels just 
above those of the APEX microarray analysis. Therefore, we 
conclude that NGS is by far more cost-effective and efficient 
than the microarray analysis in patients with arRP, and should 
be the diagnostic genetic analysis of preference.
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